NADA brings tennis players, National championship under its ambit

Image
Press Trust of India New Delhi
Last Updated : Oct 02 2018 | 6:10 PM IST

Widening its net, the National Anti-Doping Agency (NADA) has, for the first time ever, collected samples from close to 20 tennis players competing at the National Tennis Championships at DLTA Complex here.

Players such as top seed Arjun Kadhe, Siddhant Banthia, Ishaque Eqbal and former Under-14 champion Ajay Malik were among those who were randomly picked to give blood and urine samples on Monday.

A few players were asked to provide samples before their matches began while others provided samples after the matches.

"We had created a new system early this year where risk assessment, across the sports, was done. On the scientific basis of that, we worked out the test distribution plan. We identified which are the tournaments where we have to conduct test and this event came in that list, so we sent officials," NADA chief Navin Agarwal told PTI.

Not only at the national championships, the NADA has tested top Indian players in and out of competitions in international circuits this year too.

Asian Games bronze medallist Ankita Raina and top men's singles player Yuki Bhambri confirmed to PTI that they were asked by NADA to provide whereabout details and they were tested.

"I had given them six-week programme before and after the Asian Games. WADA also checks 2-3 times a year," said Ankita.

"I have provided samples to NADA officials both in and out of competition this year. On the ATP circuit, it happens regularly," said Bhambri.

While doping is not as big an issue in Indian tennis as the age fraud but it still is a welcome step.

When contacted, AITA secretary General Hironmy Chatterjee said that NADA has become "very active" this year.

Asked if the Federation would also be more active in educating the coaches, Chatterjee said, "We have with us very experienced Dr Vece Paes, who guides coaches and players at many workshops during the year."
"In Australia, ASADA has developed an APP, in which you can type the name of the medicine to know if it is banned or not. We need something like that in India too."

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 02 2018 | 6:10 PM IST

Next Story